
In Hikma Pharmaceuticals USA v. Amarin Pharma, the Supreme Court unanimously held that, to plausibly allege induced infringement under 35 U.S.C. § 271(b), a complaint must identify words or conduct that affirmatively encourage infringement....
Loading summary